A gateway to UK Biotechnology

Why Biotechnology?

Earlier identification of disease risk and diagnosis, through genetic screening
4763239-512.png
New treatments for previously untreatable conditions.
6602720-512.png
Reduced reliance on fossil fuels through biologically-produced chemicals and fuels

A sustainable future

7304538-512.png
iconfinder_laboratory-research-medical-c

Why the UK?

4 of the world's top 10 universities are in the UK
The UK government has committed to life sciences as a key sector for post-covid recovery
UK is number one cluster in Europe and is third globally
iconfinder_education-degree-course-unive
iconfinder_idea_light_bulb_brainstroming
iconfinder_ic_looks_one_48px_352531.png
885963-200 copy.png

Backed by great science

Why New Grounds?

We are building a portfolio-first venture capital fund
On average, first time funds outperform mature funds
Asset 3@4x.png
clipart2421347.png
Asset 3@4x.png
We do not think outside of the box, we remove it

A new perspective

Asset 23@4x.png

Biotech EIS Fund I

Jurisdiction
UK
Sector
Biotechnology
Stage
Seed, Pre-Series A, Series A
Ticket Size
Foundation Support
£0.1m - £1m 
5% carry to non-profit foundation
Our Portfolio
Cellesce-Logo-®-for-Enfold.png

Developed proprietary bioreactor for manufacture and scale up of patient derived organoids (PDOs) for high throughput screening. Industry leader in colorectal cancer PDOs with new cell lines being developed.

Novel graphene-based biosensor. This team has has developed a low-cost biosensor for use in analysing compound concentrations during drug development and production.

5e2899732ed18d172facbeda_HexagonFab_logo

Led by Professor Helen McCarthy of Queen's University Belfast, pHion has developed the peptide based RALA platform for precision delivery of therapeutic vaccines.

Phion-Logo-Color.webp